Neurocrine Biosciences | NBIX - Ebitda


Neurocrine Biosciences reported $193.3M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
Prothena USD 25.98M 65.51M Mar/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Repligen USD 43.77M 3.76M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Teva Pharmaceutical Industries USD 474M 581M Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026